Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4 inducer, rifampin in healthy subjects

被引：0
|
作者：
Gardin, A. [1 ]
Gray, C. [2 ]
Neelakantham, S. [3 ]
Huth, F. [1 ]
Davidson, A. M. [4 ]
Dumitras, S. [1 ]
Legangneux, E. [1 ]
Shakeri-Nejad, K. [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[4] PPD, Austin, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P796
引用
收藏
页码：409 / 409
页数：1
相关论文
共 50 条
  • [21] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Bae, Jung-Woo
    Kim, Ji-Hong
    Choi, Chang-Ik
    Kim, Mi-Jeong
    Kim, Hyung-Ji
    Byun, Seong-Ae
    Chang, Young-Soon
    Jang, Choon-Gon
    Park, Young-Seo
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2009, 32 (02) : 269 - 273
  • [22] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Jung-Woo Bae
    Ji-Hong Kim
    Chang-Ik Choi
    Mi-Jeong Kim
    Hyung-Ji Kim
    Seong-Ae Byun
    Young-Soon Chang
    Choon-Gon Jang
    Young-Seo Park
    Seok-Yong Lee
    Archives of Pharmacal Research, 2009, 32 : 269 - 273
  • [23] Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
    Shimamoto, J
    Ieiri, I
    Urae, A
    Kimura, M
    Irie, S
    Kubota, T
    Chiba, K
    Ishizaki, T
    Otsubo, K
    Higuchi, S
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) : 65 - 68
  • [24] Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
    J. Shimamoto
    I. Ieiri
    A. Urae
    M. Kimura
    S. Irie
    T. Kubota
    K. Chiba
    T. Ishizaki
    K. Otsubo
    S. Higuchi
    European Journal of Clinical Pharmacology, 2000, 56 : 65 - 68
  • [25] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [26] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [27] Effects of genetic polymorphism of CYP2C9 on the pharmacokinetics of lornoxicam in healthy Korean subjects.
    Bac, J.
    Kim, N.
    Lee, H.
    Lee, J.
    Jung, D.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S33 - S34
  • [28] Effects of CYP2C9 polymorphism on the pharmacokinetics and pharmacodynamics of meloxicam in healthy korean subjects.
    Bae, J.
    Kim, M.
    Song, Y.
    Sa, J.
    Choi, C.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S31 - S31
  • [29] CYP2C9 genetic polymorphisms significantly affected the pharmacokinetics of flurbiprofen in healthy Korean subjects
    Lim, Hye-Jin
    Kim, Dong-Hyun
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E316 - E316
  • [30] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
12345